跳至主要内容
临床试验/KCT0002198
KCT0002198已完成未知

A prospective multicenter study to evaluate the efficacy and safety of a self-expandable large cell metallic stent (Niti-S LCD type) in patients with malignant hilar biliary obstruction

Ajou University Hospital0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
21(Year) 至 o Limit(—)
性别
All

入选标准

  • (1) > 20 years of age, (2) malignant hilar biliary obstruction of Bismuth type II or higher, caused by cholangiocarcinoma or gallbladder cancer (3) unsuitable for curative resection due to locally advanced stage, metastasis, or high surgical risk.

排除标准

  • a history of prior stent placement or biliary surgery, except cholecystectomy and liver atrophy, and uncontrolled coagulopathy (International normalized ratio > 1.5 or platelet count < 50,000 /mm3).

研究者

发起方
Ajou University Hospital

相似试验

招募中
Unknown
A multicenter prospective study to evaluate the effect of elobixibat on spontaneous defecation without a feeling of residual stool in patients with chronic constipation who are inadequately effective with magnesium oxide, a first-line treatment for constipation.chronic constipation
JPRN-UMIN000048397Medical corporation Irisawa Medical Clinic26
已完成
不适用
Prospective multicenter Study to evaluate the Effect of tight and systematic monitoring by Ultrasound on Therapy and Outcome in Patients with early rheumatoid ArthritisM05Seropositive rheumatoid arthritisrheumatoid arthritis
DRKS00010485Charité Universitätsmedizin Berlin -Med. Klinik mit SP Rheumatologie und Klin. Immunologie453
尚未招募
不适用
A Prospective randomized multi-center study for efficacy of metallic biliary stent compared to plastic stent in patients receiving neoadjuvant chemotherapy for resectable pancreatic cancer
KCT0006294Yonsei University Health System, Severance Hospital196
进行中(未招募)
不适用
A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy StudyMultiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the UK is approximately 125/100,000 of the population with an annual incidence of 6/100,000. Approximately 80,000 individuals are affected with MS in the UK.
EUCTR2005-005751-18-GBCL Biomedicine R&D Unit100
尚未招募
不适用
Multicenter randamized study for evaluating the effect of dantrolene aganst heart failure and arrhythmiaheart failure
JPRN-UMIN000022756Yamaguchi University Graduate School of Medicine100